1-((4,6-bis(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)methyl)-1-methylurea | 1396392-17-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-((4,6-bis(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)methyl)-1-methylurea
• 英文别名: 1-[[4,6-bis(trifluoromethyl)-1H-benzimidazol-2-yl]methyl]-1-methylurea
• CAS: 1396392-17-8
• 化学式: C₁₂H₁₀F₆N₄O
• 分子量: 340.228
• InChiKey: SWBSIESMYBZAHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  75
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  1-(4,6-bis(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-N-methylmethanamine hydrochloride 、 尿素 以 水 为溶剂， 以72%的产率得到1-((4,6-bis(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)methyl)-1-methylurea
  参考文献：
  名称：

  [EN] BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL
  [FR] INHIBITEURS DE TYPE BENZIMIDAZOLE DU CANAL SODIQUE

  摘要：

  本发明涉及用于治疗与电压门控离子通道功能相关的疾病的化合物，特别是与钠通道活性相关的疾病。更具体地说，本发明关注的是一类化合物（例如，符合任何一种公式（I）-（XIII）或表1中的化合物（1）-（236）），这些化合物可用于治疗多种疾病和状况。公式（I）

  公开号：

  WO2012116440A1

文献信息

• BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL
  申请人：Pajouhesh Hassan

  公开号：US20140187533A1

  公开（公告）日：2014-07-03

  The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns compounds (e.g., compounds according to any of Formulas (I)-(XIII) or Compounds (1)-(236) of Table 1) that are useful in treatment of a variety of diseases and conditions. Formula (I)

  本发明涉及用于治疗与电压门控离子通道功能相关的疾病的化合物，特别是与钠通道活性相关的疾病。更具体地说，本发明涉及化合物（例如，按照任何公式（I）-（XIII）或表1的化合物（1）-（236）的化合物），这些化合物对于治疗各种疾病和病况是有用的。公式（I）
• Benzimidazole inhibitors of the sodium channel
  申请人：DeGiacomo Mark G.

  公开号：US10351514B2

  公开（公告）日：2019-07-16

  The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns compounds (e.g., compounds according to any of Formulas (I)-(XIII) and in particular Formula (X), and Compounds (1)-(236) of Table 1) that are useful in treatment of a variety of diseases and conditions.

  本发明涉及有助于治疗与电压门控离子通道功能相关的病症，特别是与钠通道活性相关的病症的化合物。更具体地说，本发明涉及有助于治疗各种疾病和病症的化合物（例如，根据式（I）-（XIII）中任一式，特别是式(X)的化合物，以及表 1 的化合物（1）-（236））。
• Cyclodextrin-Based Polymers for Therapeutic Delivery
  申请人：Cerulean Pharma Inc.

  公开号：US20140213504A1

  公开（公告）日：2014-07-31

  Described herein are CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. Also disclosed are methods of using (e.g., to treat a disorder) the CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates.
• Benzimidazole Inhibitors of the Sodium Channel
  申请人：DeGiacomo Mark G.

  公开号：US20170260130A1

  公开（公告）日：2017-09-14

  The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns compounds (e.g., compounds according to any of Formulas (I)-(XIII) or Compounds (1)-(236) of Table 1) that are useful in treatment of a variety of diseases and conditions.
• US9688615B2
  申请人：——

  公开号：US9688615B2

  公开（公告）日：2017-06-27